OPC-131461 / Otsuka - LARVOL DELTA

A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | N=264 ➔ 0 | Trial completion date: Jan 2027 ➔ May 2025 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Jan 2027 ➔ May 2025

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Cardiovascular • Congestive Heart Failure • Heart Failure

A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure (clinicaltrials.gov) - P2 | N=264 | Not yet recruiting | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF]) (clinicaltrials.gov) - P2 | N=157 | Completed | Sponsor: Otsuka Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF]) (clinicaltrials.gov) - P2 | N=155 | Recruiting | Sponsor: Otsuka Pharmaceutical Co., Ltd. | Trial completion date: Mar 2024 ➔ Sep 2024 | Trial primary completion date: Mar 2024 ➔ Sep 2024

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF]) (clinicaltrials.gov) - P2 | N=155 | Recruiting | Sponsor: Otsuka Pharmaceutical Co., Ltd.

New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure